消息面上，1月12日，药明康德发布公告，预期本公司(连同其子公司统称为：本集团)于截至2025年12 月31日止年度(本期)营业收入及归属于本公司股东的净利润相比2024年年度同期(上年同期)将取得上 升。公司预计本期实现归属于本公司股东的净利润约人民币191.51亿元，同比增长约102.65%，其中包 含了出售联营公司部分股权以及剥离部分业务所获得的投资收益；本期基本每股收益预计约人民币6.70 元╱股，同比增长约104.27%。 药明康德（603259）(02359)盈喜后高开逾4%，截至发稿，涨4.69%，报116港元，成交额3112.34万港 元。 ...

智通财经APP获悉，药明康德(02359)盈喜后高开逾4%，截至发稿，涨4.69%，报116港元，成交额 3112.34万港元。 消息面上，1月12日，药明康德发布公告，预期本公司(连同其子公司统称为：本集团)于截至2025年12 月31日止年度(本期)营业收入及归属于本公司股东的净利润相比2024年年度同期(上年同期)将取得上 升。公司预计本期实现归属于本公司股东的净利润约人民币191.51亿元，同比增长约102.65%，其中包 含了出售联营公司部分股权以及剥离部分业务所获得的投资收益；本期基本每股收益预计约人民币6.70 元╱股，同比增长约104.27%。 ...

Core Viewpoint - The A-share market shows strong performance with 140 companies releasing earnings forecasts for 2025, indicating significant profit growth for many firms, particularly WuXi AppTec, which is highlighted for its substantial profit increase driven by asset sales [1][2]. Group 1: Company Performance - WuXi AppTec expects revenue of approximately 45.457 billion yuan for 2025, a year-on-year increase of about 15.84%, with net profit projected at around 19.151 billion yuan, reflecting a significant increase of approximately 102.65% [1]. - The profit growth for WuXi AppTec is primarily attributed to the sale of partial equity in joint ventures and the divestiture of certain business segments, with net gains from these sales estimated at about 4.161 billion yuan and 1.434 billion yuan respectively [1]. - Even excluding non-recurring gains, WuXi AppTec anticipates a net profit of 13.241 billion yuan, marking a year-on-year increase of approximately 32.56%, achieving a historical high [1]. Group 2: Industry Trends - Among the companies that have released earnings forecasts, 72 firms reported net profits exceeding 100 million yuan, with 22 companies surpassing 1 billion yuan [2]. - Notable companies with net profits exceeding 10 billion yuan include Zijin Mining, WuXi AppTec, Luxshare Precision, and Shanghai Port Group, with respective profits of 51.5 billion yuan, 19.151 billion yuan, 16.852 billion yuan, and 13.4 billion yuan [2]. - Shanghai Port Group reported a revenue of 39.44 billion yuan for 2025, a year-on-year growth of 3.5%, despite a net profit decline of 10.4% [2]. Group 3: Growth Leaders - In terms of net profit growth rates, 19 companies achieved over 100% growth compared to the same period in 2024, with the top four being Zhongke Lanyun, Chuanhua Zhili, Bai'ao Saitou, and Kangchen Pharmaceutical, with growth rates of 371.51%, 308.82%, 303.57%, and 279% respectively [3]. - Zhongke Lanyun expects revenue between 1.83 billion yuan and 1.85 billion yuan, with a net profit forecast of 1.4 billion to 1.43 billion yuan, reflecting a growth of 366.51% to 376.51% [3]. - Chaohongji anticipates a net profit of 436 million to 533 million yuan, representing a year-on-year increase of 125% to 175%, driven by enhanced product and brand strength [3].

Policy Trends - The National Medical Insurance Administration has intensified anti-corruption efforts in the medical sector, highlighted by a case involving a doctor who accepted kickbacks totaling 789,100 yuan from pharmaceutical companies between 2012 and 2023 [1] - The Central Commission for Discipline Inspection has emphasized the need to address issues such as "kickback sales" and has included them in the scope of strict investigation [1] Drug Approval - Hualan Biological announced that its subsidiary received a notice of acceptance for the domestic production registration application of Adalimumab injection, a biosimilar drug for treating various immune diseases [1] - China Resources Double Crane's subsidiary has received implied permission from the FDA for clinical trials of the new drug DC6001 [2] - Heng Rui Medicine's SHR-1826 injection has been included in the list of breakthrough therapy varieties by the National Medical Products Administration [3] Financial Disclosures - WuXi AppTec expects a net profit of 19.151 billion yuan for 2025, representing a year-on-year increase of approximately 102.65% [4] - Sharp Eye's projected net profit for 2025 is expected to be negative due to anticipated goodwill impairment [5] Industry Developments - Haixiang Pharmaceutical has signed an innovative drug cooperation agreement with Wanbangde Pharmaceutical to develop treatments for amyotrophic lateral sclerosis, with Haixiang providing 150 million yuan in funding [6] - Innovation Medical's product, Cyberlink AC5, was officially launched in October 2025, generating revenue of 114,000 yuan, while the AM5 product has completed clinical trials but has not yet generated revenue [6] Regulatory Actions - The National Medical Products Administration has initiated an investigation into Anhui Telunshake Biotechnology for violations of cosmetic production regulations, leading to a halt in production and a requirement for corrective actions [7]

登录新浪财经APP 搜索【信披】查看更多考评等级 【头条要闻】 "抛售美国"卷土重来！美联储风波引爆避险交易，黄金白银双双狂飙刷新高 投资者目睹特朗普政府对美联储主席杰罗姆・鲍威尔启动刑事调查后，决定重启 "抛售美国" 交易策 略，大举减持美股、美债与美元资产。美股在周一早盘小幅下挫。道琼斯工业平均指数下跌 159 点，跌 幅 0.32%；更能反映市场全貌的标准普尔 500 指数下跌 0.14%；以科技股为主的纳斯达克综合指数下跌 0.1%。美元兑其他主要货币汇率走弱。追踪美元兑六种主要货币汇率的美元指数下跌 0.35%。 A股突发！多只牛股、涨停股、概念股齐发公告提示风险 A股商业航天概念持续火爆。1月12日，多只概念股继续大涨，永赢国证商用卫星通信产业ETF、富国中 证卫星产业ETF等相关基金涨停。1月12日晚，多只商业航天概念股发布异动公告，提示股价存在炒作 风险。不少公司披露了与商业航天相关的业务及产品收入情况。 中科星图公告称，公司目前主营业务分布仍主要聚焦空天信息服务，低空经济及商业航天为公司业务拓 展的两大新兴领域。2025年1月至9月，公司商业航天相关收入占整体营业收入比例为13.89%。当前 ...

Core Viewpoint - WuXi AppTec Co., Ltd. is expected to achieve significant growth in its 2025 financial performance, driven by its integrated CRDMO business model and strategic focus on enhancing production capabilities and operational efficiency [2][9]. Financial Performance Forecast - The company anticipates a revenue of approximately RMB 45.46 billion for 2025, representing a year-on-year increase of about 15.84%, with revenue from continuing operations expected to grow by approximately 21.40% [5][6]. - Adjusted net profit attributable to shareholders is projected to be around RMB 14.96 billion, reflecting a year-on-year growth of approximately 41.33% [6]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to be about RMB 13.24 billion, with a year-on-year increase of approximately 32.56% [6]. - The total net profit attributable to shareholders is forecasted to be around RMB 19.15 billion, showing a substantial year-on-year growth of approximately 102.65%, which includes gains from the sale of equity interests and divestitures [3][6]. - The basic earnings per share are expected to be approximately RMB 6.70, marking a year-on-year increase of about 104.27% [3][6]. Business Model and Growth Drivers - The company continues to focus on its unique "integrated, end-to-end" CRDMO business model, addressing customer needs for empowerment and expanding new capabilities while optimizing production processes [2][9]. - The growth in revenue and profit is attributed to the company's commitment to delivering new and effective drugs to global patients [9]. Non-Operating Gains - Non-operating gains are expected to significantly impact net profit, primarily from the sale of a portion of equity in WuXi XDC Cayman Inc., estimated at approximately RMB 416.09 million, and the sale of 100% equity in two other companies, expected to yield around RMB 143.38 million [10].

剑桥科技(06166)控股子公司通过高新技术企业认定 智谱(02513)回应与出行平台合作不涉内幕消息 业务推进属日常范畴 重大事项： 红星冷链(01641)：香港公开发售获2309.25倍认购 每股发售价12.26港元 BBSB INTL(08610)：公开发售获10745.13倍认购 每股发售价0.6港元 兆易创新(03986)香港公开发售获542.22倍认购 全球发售净筹约46.11亿港元 恒瑞医药(01276)：注射用SHR-1826被药审中心纳入突破性治疗品种名单 百奥赛图-B(02315)通过基于选择权的评估框架与育世博达成进一步合作共同推进同类首创双特异性抗 体双药物偶联物项目 东风集团股份(00489)2025年度累计汽车销量为189.62万辆 同比增长约0.01% 中银航空租赁(02588)2025年全年自有飞机利用率保持在100% 龙湖集团(00960)2025年度累计实现总合同销售金额631.6亿元 中国软件国际(00354)投资企业MiniMax(00100)港交所上市 全栈AI战略版图再拓新篇 达力普控股(01921)拟300万沙特里亚尔出售达力普国际40%股权 引入沙特战略投资者推 ...

Core Viewpoint - WuXi AppTec (603259.SH) has released an earnings forecast for 2025 that exceeds its previously raised guidance, indicating strong revenue and net profit growth driven by its integrated CRDMO model and non-recurring gains from asset disposals [1] Group 1: Financial Performance - The company expects to achieve a total revenue of 45.456 billion yuan in 2025, representing a year-on-year increase of 15.84%, with core business revenue growing approximately 21.40% [1] - Adjusted net profit attributable to shareholders is projected to be 14.957 billion yuan, reflecting a year-on-year growth of about 41.33%, while net profit attributable to the company’s shareholders is expected to reach 19.151 billion yuan, marking a significant increase of approximately 102.65% [1] - The company has raised its annual revenue guidance for the second time within a year, adjusting the expected range from 42.5-43.5 billion yuan to 43.5-44 billion yuan [1] Group 2: Business Segments - The TIDES business (oligonucleotides and peptide drugs) has shown remarkable performance, with revenue reaching 7.84 billion yuan in the first three quarters, a year-on-year increase of 121.1%, setting historical highs for both the first three quarters and the third quarter [2] - Non-recurring gains from asset disposals have significantly contributed to the earnings exceeding expectations, with net gains from the sale of certain equity stakes totaling 5.595 billion yuan, accounting for 37.41% of the expected annual net profit [2] Group 3: Strategic Focus - The company is focusing on its core CRDMO areas by divesting from clinical research services, which has resulted in a gain of 1.434 billion yuan from the sale of related businesses [2] - WuXi AppTec is expanding its global footprint with ongoing construction of overseas bases in Singapore and Delaware, aiming to mitigate geopolitical risks and better meet customer demands [3] - Revenue from U.S. clients has reached 22.15 billion yuan in the first three quarters of 2025, reflecting a year-on-year growth of 31.9% and increasing its share of total revenue to 67%, becoming a key growth driver [3]

今日焦点 华是科技：控股股东、实际控制人等筹划控制权变更事项，股票停牌 华是科技公告称，公司控股股东、实际控制人俞永方、叶建标和持股5%以上股东章忠灿正在筹划重大 事项，可能导致公司控制权发生变动。为保证公平信息披露，维护投资者利益，避免造成公司股价异常 波动，公司股票自2026年1月13日开市起停牌，预计停牌时间不超过2个交易日。停牌期间，公司将根据 事项进展情况，严格按照法律法规的规定和要求履行信息披露义务。待上述事项确定后，公司将及时披 露相关公告并申请公司股票复牌。 卓易信息发布异动公告，公司IDE业务在2024及2025年陆续发布了两款AI编程产品，尚处于市场导入 期，在初步商业化阶段，产品技术路径、编程效果及市场接受度存在不确定性，目前尚未形成规模化的 产品体系，技术迭代及商业化进展可能不及预期。目前两款产品使用用户以免费用户为主，尚未形成稳 定、可持续的收入来源。未来产品的收入规模、盈利水平及现金流贡献存在高度不确定性，短期内对公 司整体经营业绩影响有限。DeepSeek、通义千问等均系开源大语言模型，任何用户皆可免费基于该模 型开展训练工作，进而进行个性化开发或模型优化，以满足不同用户在多元场 ...

Core Viewpoint - WuXi AppTec expects to achieve a revenue of approximately RMB 4,545,617 million in 2025, representing a year-on-year growth of about 15.84% [1] - The revenue from continuing operations is projected to grow by approximately 21.40% year-on-year [1] - The company anticipates a net profit attributable to shareholders of approximately RMB 1,915,058 million, reflecting a year-on-year increase of about 102.65% [1] Summary by Category - **Revenue Projections** - Expected revenue for 2025 is approximately RMB 4,545,617 million, with a growth rate of 15.84% compared to the previous year [1] - Revenue from continuing operations is projected to grow by 21.40% year-on-year [1] - **Net Profit Expectations** - Anticipated net profit for shareholders is around RMB 1,915,058 million, indicating a significant increase of 102.65% year-on-year [1]